XML 48 R31.htm IDEA: XBRL DOCUMENT v3.6.0.2
Selected Quarterly Financial and Supplementary Data
12 Months Ended
Dec. 31, 2016
Notes to Financial Statements  
Quarterly Financial Information [Text Block]
CAMBREX CORPORATION AND SUBSIDIARIES
 
SELECTED QUARTERLY FINANCIAL AND SUPPLEMENTARY DATA - UNAUDITED
(in thousands, except
 
per share data)
 
 
 
1st
 
 
2nd
 
 
3rd
 
 
4th
 
 
 
Quarter
 
 
Quarter
 
 
Quarter
 
 
Quarter
 
2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gross sales
  $
93,935
    $
119,054
    $
99,867
    $
178,682
 
Net revenues
   
94,741
     
118,638
     
99,399
     
177,866
 
Gross profit
   
38,899
     
48,557
     
37,602
     
79,167
 
Income from continuing operations (1)
   
14,845
     
20,810
     
13,721
     
37,949
 
Loss from discontinued operations (3)
   
(263
)    
(316
)    
(4,503
)    
(565
)
Net income
   
14,582
     
20,494
     
9,218
     
37,384
 
                                 
Earnings per share of common stock: (4)
                               
Basic
   
0.46
     
0.64
     
0.29
     
1.16
 
Diluted
   
0.44
     
0.62
     
0.28
     
1.13
 
Average shares:
                               
Basic
   
31,886
     
32,063
     
32,149
     
32,240
 
Diluted
   
32,771
     
32,926
     
32,999
     
33,107
 
                                 
 
 
 
1st
 
 
2nd
 
 
3rd
 
 
4th
 
 
 
Quarter
 
 
Quarter
 
 
Quarter
 
 
Quarter
 
2015
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gross sales
  $
78,184
    $
106,379
    $
92,350
    $
156,943
 
Net revenues
   
77,525
     
106,635
     
92,979
     
156,187
 
Gross profit
   
29,079
     
45,945
     
35,680
     
66,261
 
Income from continuing operations (2)
   
8,368
     
19,450
     
11,876
     
17,482
 
(Loss)/income from discontinued operations (3)
   
(375
)    
213
     
(129
)    
332
 
Net income
   
7,993
     
19,663
     
11,747
     
17,814
 
                                 
Earnings per share of common stock: (4)
                               
Basic
   
0.26
     
0.63
     
0.37
     
0.56
 
Diluted
   
0.25
     
0.61
     
0.36
     
0.54
 
Average shares:
                               
Basic
   
31,198
     
31,344
     
31,471
     
31,661
 
Diluted
   
32,158
     
32,440
     
32,593
     
32,784
 
 
(1)
Income from continuing operations for the
first,
second,
third,
and
fourth
quarters includes
$290
of expense,
$154
of expense, a
$47
benefit and
$761
of expense, respectively, for restructuring related to the decision to sell our finished dosage form facility in Hyderabad, India.
 
(2)
Income from continuing operations in the
fourth
quarter includes restructuring expenses of
$15,573
and a tax benefit of
$1,464
related to the decision to sell our finished dosage form facility in Hyderabad, India.
 
(3)
Discontinued operations include charges and reimbursements for environmental remediation related to sites of divested businesses.
 
(4)
Earnings per share calculations for each of the quarters are based on the weighted average number of shares outstanding for each period. As such, the sum of the quarters
may
not necessarily equal the earnings per share amount for the year.